NCT07169162View on ClinicalTrials.gov

ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2019

Primary Completion Date

September 5, 2025

Study Completion Date

September 5, 2025

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

ADZENYS XR-ODT

ADZENYS XR-ODT™ (amphetamine) is an extended-release orally disintegrating tablet approved for once-daily oral administration for the treatment of ADHD in patients 6 years and older.

DRUG

Placebo Oral Tablet

Participants in this arm will be given placebo as matching ODT once daily during the double-blind treatment period.

Trial Locations (1)

89128

Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas

Sponsors

Collaborators (1)

Premier Research
All Listed Sponsors
collaborator

Premier Research

OTHER

lead

Aytu BioPharma, Inc.

INDUSTRY

NCT07169162 - ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder | Biotech Hunter | Biotech Hunter